Ludlow BioVentures
Member of the Ludlow Biotech Stock Index - Click Here

Cryoport, Inc. 
OTC: CYRX		 Stock Report Launch
April 30, 2008
OTC Symbol: CYRX
Sector: Biotechnology
Sub-Industry: support technology
Fully Reporting: Yes
Summary: The Company develops leading edge, proprietary, technology-driven shipping and storage products for use in the rapidly growing global biotechnology and biopharmaceutical cold chain.
Price at Research Launch:  $0.97

|

 52-Week Range: $0.50-$2.40

Prepared by: Ludlow Capital Research
Business Summary 
  • CryoPort develops leading edge, proprietary, technology-driven shipping and storage products for use in the rapidly growing global biotechnology and biopharmaceutical cold chain. The products developed by CryoPort are essential components of the infrastructure required for the testing, research and end user delivery of temperature-sensitive medicines and biomaterials in an increasingly complex logistical environment. www.cryoport.com

     

Quantitative Evaluations 
Ludlow Capital Rating: B-
D C B- B B+ A- A A+

Volatility: Average
Low Average High

Technical Rating: BULLISH

Relative Stock Strength: 54
54
1 Lowest Highest 99


INVESTMENT OPINION



Ludlow BioVentures Updates Research Coverage on Cryoport, Inc. (CYRX)
Last Updated: August 15, 2008 - 7:43am EST

NEW YORK--Ludlow Bio Ventures updates research opinion on Cryoport, Inc. (OTC: CYRX), a leading supplier of affordable temperature sensitive shipping solutions for the frozen biopharmaceutical industry, maintains B- rating, issues near-term price target of $1.50 per share.


Summary

On August 14, 2008, the company filed their 10 report with the SEC, which showed minimum revenues of $13,424, as compared to $5,541 for the same period in 2007. Net loss jumped to ($8,222,481), as compared to ($745,508) for the same period in 2007. This dramatic jump was attributed to the extinguishment of debt, which we believe should be a one time event.

What is needed now for the company is news of signed contracts with biotech companies to use their new Cryoport Express System, as this would be the catalyst to send the company to the next level.

The CryoPort Express system provides a much needed commercial service to biotech and pharmaceutical companies needing to ship temperature sensitive material through a trusted 'cold chain' supply chain. On Dec. 19, 2007, the company announced that it had named Federal Express (FedEx) as its global shipping provider for its CryoPort Express system. Extreme condition test results out of India have shown positive results, and a potential client in the region has requested the company to focus their efforts on developing a plan for the entire Asia Pacific region.

Unlike biotechnology or drug stocks, where one has to go through an extensive FDA phase study program that may take months if not years, Cryoport has a commercial industry service that may start generating revenues for the company once launched. Instead of trying to find the next big drug or technological breakthrough, it may be wiser to look at companies that services this industry and have more immediate possibilities for revenue recognition.

Ludlow BioVentures is maintaining its B- rating on the company, and issuing a near-term price target of $1.50 per share.

 CYRX Research Opinion Newsletter Sign-up to receive free updates on the biotechnology sector, and stocks we follow.


Cash Flow

As of June 30, 2008, the company had $2,189,698 of cash on hand. It is in Ludlow Bioventure's opinion that this should provide the company with enough working capital in the foreseeable future.


What to Look for Next

This section gives investors a general idea on what next to watch for to indicate the company is moving forward on their business plan.

For Cryoport, Inc., it's all about signing new biotech firms for their Cryoport System. Any news of new biotech clients for their cold chain shipping system will indicate the company is moving ahead, and taking the next step in its business model.


Technical Analysis

The stock has come off its lows from early July, and is currently testing its 200 day moving average at $0.95 a share, which is now resistance. Any move above this long term trend line would indicate a bullish signal.

About CryoPort

CryoPort develops leading edge, proprietary, technology-driven shipping and storage products for use in the rapidly growing global biotechnology and biopharmaceutical cold chain. The products developed by CryoPort are essential components of the infrastructure required for the testing, research and end user delivery of temperature-sensitive medicines and biomaterials in an increasingly complex logistical environment. www.CryoPort.com


About Ludlow BioVentures, Inc

Based in New York City, Ludlow BioVenture is a venture capital and research advisory firm with a specific focus on the biotechnology sector. The goal of the firm is to promote investments into biotech ventures worldwide. Ludlow BioVentures owns and operates the Ludlow BioVenture Index, which tracks a wide basket of US traded large and small cap biotechnology stocks. www.ludlowcapital.com/bioventures/

------------------------

Contact:

Ludlow BioVentures, Inc. 
Research Department 
Phone: (212) 233-2864 
Email: info@ludlowcapital.com 



Key Stock Statistics
As of June 30, 2008
12 Month P/E NA | Yield NiL
Shs. outstanding 41m Shareholders UR
Shs. restricted UR Market cap. (M) $38.8m
Avg. daily vol. (K) 52k Inst. holdings 0%

Value of $10,000 invested 1 year ago: UR


Dividend Data

No dividends have been paid on the common stock.
Revenues/Earnings Data
Fiscal year ending December 31
Revenues (thousands$)
2008 2007 2006 2005 2004 2003
1Q $13.4 $5.5 UR
2Q UR UR UR  
3Q UR UR UR
4Q -- UR UR    
Yr. NA


Earnings per Share ($)
2008 2007 2006 2005 2004 2003
1Q (0.20) (0.02) NA
2Q -- UR NA    
3Q -- UR NA
4Q -- UR NA      
Yr. -- UR UR


Source: Company Press Release, and filings with SEC.
 
Legend: E-Estimated. NA-Not Available. NM-Not Meaningful. NR-Not Ranked. UR-Under Review.
Office: 20382 Barents Sea Circle
Lake Forest, CA 92630
Telephone: 949-470-2300
Email: stuart@carpedminc.com		 CEO: Peter Berry
CFO: Dee S. Kelly CPA
Auditor: 
Website: www.cryoport.com		 Founded: UR
Domicile: CA
Employees: 4
Analyst: Thomas Latino, PhD
For important regulatory information, go to "Disclaimer"
All of the views expressed in this research report accurately reflect our quantitative research models regarding any and all of the subject securities or issuers. No part of our compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed in this research report.
This report is for information purposes and should not be considered a solicitation to buy or sell any security. Neither Ludlow Capital nor any other party guarantees its accuracy or makes warranties regarding results from its usage. Ludlow Capital receives compensation from the issuer or an agent thereof for initiating coverage, and for distribution including licensed redistribution of this report, and/or for inclusion in other Ludlow Capital publications, generally in amounts up to U.S. $5,000 per year. Ludlow Capital was compensated for the distribution of this research material. Redistribution is prohibited without written permission.

Disclaimer:

This is NOT a solicitation to Buy or Sell any security, but rather is for research purposes only. Content contained herein includes facts, views, opinions and recommendations of individuals and organizations deemed of interest. Ludlow BioVentures does not guarantee the accuracy, completeness or timeliness of, or otherwise endorse these views, opinions or recommendations, or give investment advice. Ludlow BioVentures, its affiliates, or directors, may or may not hold a position in the above security from time to time, and investors are encourage to consider this as a possible conflict of interest when reviewing this information. In Compliance with SEC Rule 17B Ludlow BioVentures was compensated thirthy-thousand restricted 144 shares, and eight-hundred dollars a month for this research report and distribution, and should be considered a possible conflict of interest when reviewing this report and information. 

Safe Harbor Statements:

This research report includes statements that may constitute forward-looking statements made pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Although the Company believes that the expectations reflected in such forward-looking statements are based on reasonable assumptions, such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected.

(NOTE: Ludlow Capital is NOT a broker-dealer, and does not offer buy or sell recommendations. Ludlow Capital's reports are strictly independent investment opinions, and does not hold any positions in the companies we cover unless otherwise clearly stated in our report. Rather, we offer our subscribers a perspective on each investment from our years of experience in dealing with small and micro-cap companies. We update our investment opinions and commentaries throughout the year, and encourage any interested investors to subscribe to our yearly membership to receive regular updates on these companies.)
@ Copyright  2005 - Ludlow Capital, Inc.

A Ludlow Capital Company